---
source_pdf: "https://drive.google.com/file/d/1jVZO8f_6T9XiWfg44OLSF7kotWTn2WcN/view"
drive_folder: "Research"
type: research

ingested: 2025-12-27
original_filename: "Ryght Investor Deck 19JULY2024.pdf"
---

> **Original:** [View Original PDF](https://drive.google.com/file/d/1jVZO8f_6T9XiWfg44OLSF7kotWTn2WcN/view)

# Ryght Investor Presentation

## Slide 1: RIGHT.

**Investor Presentation**
June 2024

©2024 Ryght, Inc. All Rights Reserved. CONFIDENTIAL. Do not distribute or reproduce.

## Slide 2: Vision

**Vision**

To accelerate drug development through an AI-driven, real-time global network of patients, sites, and sponsors to simplify trials, speed time to market and save lives

© 2024 Ryght, Inc. All Rights Reserved. CONFIDENTIAL. Do not distribute or reproduce.

## Slide 3: The Problem

**The Problem**
The increasing volume and complexity of clinical trials is crippling existing antiquated systems

**66,000 recruiting studies and growing**
**44%** Are in the US

**Chart: Number of Registered Studies Over Time and Some Significant Events (as of 2024-05-10)**
* Y-axis: Number of Registered Studies Significant Events (0 to 500,000)
* X-axis: Year (2000, 2006, 2012, 2018, 2024)

| Year | Number of Registered Studies Significant Events |
|---|---|
| 2000 | ~25,000 |
| 2006 | ~100,000 |
| 2012 | ~200,000 |
| 2018 | ~300,000 |
| 2024 | ~475,000 |

**Many trials compete for the same patients**

**Studies are more complex and take longer**

**....$2.6B**
To develop a single drug

©2024 Ryght, Inc. All Rights Reserved. CONFIDENTIAL. Do not distribute or reproduce.

## Slide 4: The solution

**The solution**
Leveraging AI to build a unique network of connected sites, sponsors & CROs

**RESEARCH SITES**
* Smooth operations
* Improve site capabilities
* Bring more options to patients
* Increase revenue
* Free of Charge for Research

**SPONSORS & CROs**
* Analyze data
* Generate documents
* Communicate with sites
* Onboard the “Ryght sites” for trials
* Complete studies faster

**ECOSYSTEM PARTNERS**
* Build GenAI into their offerings and leverage Ryght network

©2024 Ryght, Inc. All Rights Reserved. CONFIDENTIAL. Do not distribute or reproduce.

## Slide 5: The vision

**The vision**
AI to automate connected sites, sponsors & CROs

*   **Sponsors** (connected to AI)
*   **CROs** (connected to AI)
*   **Sites** (connected to AI)

©2024 Ryght, Inc. All Rights Reserved. CONFIDENTIAL. Do not distribute or reproduce.

## Slide 6: The Opportunity

**The Opportunity**

**Chart: GLOBAL CLINICAL TRIAL MARKET SIZE, 2023**
* Total Market Size: **$81B**
* Growing at 11% CAGR

| Segment                           |
|-----------------------------------|
| Pharmaceutical & Biopharmaceutical Companies |
| Medical Device Companies          |
| Others                            |

**Labor accounts for 80%-95% of a clinical trial's direct costs.**

**Ryght GenAI reduces friction, improves efficiency and speeds time to market**

©2024 Ryght, Inc. All Rights Reserved. CONFIDENTIAL. Do not distribute or reproduce.

## Slide 7: Company

**Company**

© 2024 Ryght, Inc. All Rights Reserved. CONFIDENTIAL. Do not distribute or reproduce.

## Slide 8: Team

**Team**
Former Deep Lens team working together to go much bigger

**Simon Arkell, CEO & Co-Founder**
Founder Deep Lens (exit), Predixion (exit), B. Econ., MBA, Olympian

**John Crupi, CTO & Co-Founder**
JackBe (exit), Predixion (exit), Software AG, Sun Microsystems (CTO Web Services). Real time streaming analytics expert. BS, MS. Early Deep Lens advisor

**Alex Dickinson, Exec Chair & Co-Founder**
Founder Luxtera ($660M exit), Helixis ($105M exit) and Chromacode. SVP Illumina. BE, MBA, PhD (AI). PRA board member whose introduction led to Deep Lens exit.

**Tyrone Richardson, CCO & Co-Founder**
VP Sales Deep Lens (exit), Caris, Inform Diagnostics. BS (bus), MBA.

**Dr. Chadi Nabhan, MD MBA, CMO**
Award winning Hematologist & Oncologist, Prior Chief of Oncology, Researcher, Author, Podcaster, prior CMO of significant industry players in GPO, healthtech, and a leader in precision medicine. Deep Lens advisor

**Dr. Deborah Fridman, PsyD, RN, SVP of Clinical Operations**
SVP, Clinops, Immunity Bio ($4B biotech); Exec Director of clinical research, Hoag Hospital - Deep Lens' first site.

©2024 Ryght, Inc. All Rights Reserved. CONFIDENTIAL. Do not distribute or reproduce.

## Slide 9: The Ryght solution

**The Ryght solution**

*   **World class AI software platform**
    *   Secure, industry trained, future proof. Completed 2023
*   **Industry leading site & sponsor copilots**
    *   AI copilots to help sites, sponsors and CROs run smoothly, grow revenues, reduce cost and identify new opportunities. 2024 and beyond
*   **Global Ryght Network**
    *   AI enabled sites, CROs, sponsors and partners utilizing AI as an underlying fabric to connect systems, and to connect to each other. Build out 2024, scale 2025

**Screenshot of Ryght UI showing "Medical Code Analysis" copilot:**
*   **Q: What is the primary use case for this medical code vocabulary?**
*   **Jonathan:** The primary use case for the medical code vocabulary used by Ryght is to facilitate the organization, retrieval, and analysis of biomedical literature. This vocabulary consists of standardized codes that represent various medical concepts, such as diseases, symptoms, treatments, and biological processes. By applying these codes to the vast amount of biomedical literature available, Ryght enables users to efficiently search for relevant information and extract valuable insights. The medical code vocabulary serves as a common language that allows researchers, healthcare professionals, and other users to communicate and share information effectively. It helps in categorizing and indexing scientific articles, clinical trials, and other sources of biomedical knowledge, making it easier to navigate and access the vast amount of information in the field. Furthermore, the medical code vocabulary enables Ryght to generate summaries and translations of scientific articles. By understanding the context and meaning behind the codes, Ryght can extract key information from the literature and present it in a concise and understandable manner. This empowers users to quickly grasp the main findings, implications, and relevance of the research, saving them time and effort in staying up-to-date.
*   **Ask another question...**
*   **Include the following references:** Documents, Collections, Data Sources

©2024 Ryght, Inc. All Rights Reserved. CONFIDENTIAL. Do not distribute or reproduce.

## Slide 10: The Ryght Platform

**The Ryght Platform**
Launched Jan 2024.

*   **Life Science Domain Expertise** (Icon of a brain-like structure with a gear)
*   **Secure, Enterprise Scale** (Icon of a padlock with a "0" inside)
*   **Connect Enterprise Data** (Icon of connected documents)

©2024 Ryght, Inc. All Rights Reserved. CONFIDENTIAL. Do not distribute or reproduce.

## Slide 11: Platform: Secure public and client data & models

**Platform: Secure public and client data & models**

*   **Public industry resources**
    *   PubMed
    *   ClinVar
    *   OHDSI
    *   NATIONAL CANCER INSTITUTE NIH GDC Data Portal
    *   ICD-10 www.cms.gov/ICD10
    *   MeSH
*   **Enterprise data connectors**
    *   PDF icon
    *   X icon
    *   W icon
*   **Commercial and open source models**
    *   redis
    *   A (Amazon icon)
    *   C (Google Cloud icon)
    *   OpenAI
    *   Hyena DNA (molecule icon)
    *   cpt
    *   aws

**Screenshot of Ryght app showing "What are the warning signs for metabolic syndrome?"**
*   The warning signs for metabolic syndrome include:
    1.  Abdominal obesity: waist circumference greater than 102 cm (men) or greater than 88 cm (women) according to NCEP definition, or greater than 94 cm (men) or greater than 80 cm (women) according to IDF definition.
    2.  Insulin resistance: Blood glucose levels greater than 5.6 mmol/L (100 mg/dL) or drug treatment for elevated blood glucose.
    3.  Dyslipidemia: Low levels of HDL cholesterol (less than 1.0 mmol/L in men or less than 1.3 mmol/L in women) or high levels of triglycerides (greater than 1.7 mmol/L or 150 mg/dL) or drug treatment for low HDL cholesterol or elevated triglycerides.
    4.  Hypertension: Blood pressure levels greater than 130/85 mmHg or drug treatment for hypertension. It is important to note that different organizations may have slightly different criteria for defining metabolic syndrome, but these are the common warning signs.
*   Source: The clinical epidemiology of the metabolic syndrome.
*   Learn more: The epidemiology of the metabolic syndrome explained.
*   Next...
*   Suggested copilots on your library: Clinical Document Builder, Biomedical Literature Analysis, Private Document Collection.
*   My Library: Biomarkers, Docs, Approval, Component, Component Input.

©2024 Ryght, Inc. All Rights Reserved. CONFIDENTIAL. Do not distribute or reproduce.

## Slide 12: Platform: Where we sit in the stack

**Platform: Where we sit in the stack**

*   **Application (copilot) Layer**
    *   RIGHT. Copilots
    *   Customer Copilots
    *   SDK
    *   Copilot Builder
*   **Platform Layer**
    *   API
    *   RIGHT. (with Auth2, Analytics, Org Admin Portal icons)
*   **Model Layer**
    *   (ChatGPT logo)
    *   AI (Google AI logo)
    *   Gemini (Google Gemini logo)
    *   All Opensource (Happy face icon)
*   **Infrastructure Layer**
    *   aws (AWS logo)
    *   Azure (Azure logo)
    *   (Google Cloud logo)
    *   ORACLE (Oracle logo)

©2024 Ryght, Inc. All Rights Reserved. CONFIDENTIAL. Do not distribute or reproduce.

## Slide 13: Platform: Scaling with self service tools

**Platform: Scaling with self service tools**

**No-Code Builder**

**Screenshot: Copilot Details - Breast Cancer Research Copilot**
*   **General**
    *   Breast Cancer Research Copilot
    *   Our internal researchers to respond to PI requests quickly
*   **Add suggestions**
    *   Suggestion 1: Based on this collection what are the major causes of breast cancer
    *   Suggestion 2: Describe the diagnostic process for stage 3 breast cancer
    *   Suggestion 3: What is SOC therapy for TNB in Brazil?
    *   Suggestion 4: Explain the relevance of BRCA mutations in LOH scoring
    *   External URL: Enter URL
*   Published (Toggle switch)
*   Save button

**Examples of Copilots:**
*   Site Feasibility for CROs
*   Breast Cancer Research Copilot
*   Acute Pain Management
*   Sargon Overview

**SDK**

**Screenshot: Code Snippet**
```python
In [1]:
from dotenv import find_dotenv
from ryght.utils import FlowTypes
from ryght.configs import Credentials
from ryght.clients.user import RyghtClient, DevClient
from ryght.models import ChunkedDocumentCollection, JsonDocument
from ryght.utils import initialize_logging, ModelOperation
from ryght.utils import QnARating
from result import Result, Ok, OkErr

In [2]:
import logging
logger = initialize_logging('../logs/playground.logs', log_level=logging.DEBUG)

In [3]:
# Create Ryght User Client
# Provide Credentials via dictionary
creds = {
    'username': 'userid',
    'password': 'Password',
    'client_id': 'client_id',
    'client_secret': 'fsdfsdf',
    'organization': 'Ryght Community'
}
# Load credentials from environment variable
```

**Screenshot: Nmible Patient Payments dashboard**
*   AB0001 in Essential Hypertension
*   Sponsor Xample Therapeutics
*   Budget: £12,000.00
*   Current Spend: £1,560.00
*   Budget Rem: 87%
*   Payment Summary
*   Visit Schedule
*   Patients
*   Pending Payments (1)

©2024 Ryght, Inc. All Rights Reserved. CONFIDENTIAL. Do not distribute or reproduce.

## Slide 14: Copilots to support the entire drug development process

**Copilots to support the entire drug development process**
Current Roadmap

**Ryght Trial AI (Data/AI Moat)** is at the center, connecting various copilots.

**Sites:**
*   **Pre-Trial:**
    *   Literature Review (Copilot)
    *   Competitive Intel (Copilot)
    *   Study Design (Copilot)
    *   Protocol Drafting (Copilot)
    *   Informed Consent Writer (Copilot)
    *   Consent Forms (Copilot)
    *   Study Feasibility (Copilot) -> Feasibility Response
    *   Site Selection (Copilot) -> Site Initiation
*   **Clinical Trial:**
    *   Patient Enrollment (Copilot)
    *   Doc and Reporting (Copilot)
*   **Post-Trial:**
    *   Manuscript Drafting (Copilot)
    *   Regulatory Docs (Copilot)
*   **CUSTOM SITE COPILOTS**

**Sponsors & CROs:**
*   **Pre-Trial:**
    *   Study Discovery (Copilot)
    *   Proposal Writer (Copilot)
    *   Protocol Writer (Copilot)
    *   Chat with Regulatory (Copilot)
    *   Informed Consent Writer (Copilot)
    *   Chat With Protocol (Copilot)
    *   Feasibility Solution (Connected to Feasibility Request)
    *   Site Selection (Copilot)
*   **Clinical Trial:**
    *   Real-time enrollment
    *   Problem Studies
    *   Audit and Data Quality (Copilot)
*   **Post-Trial:**
    *   Manuscript Drafting and Submission (Copilot)
    *   Pharmacovigilance (Copilot)

©2024 Ryght, Inc. All Rights Reserved. CONFIDENTIAL. Do not distribute or reproduce.

## Slide 15: First copilots

**First copilots**

*   **Informed Consent Builder**
    *   Create an ICF in one hour, not 20
    *   Adheres to multiple regulatory bodies such as the US, EMEA, Australia, & Japan
    *   Helps for IITs and Grant submissions.

*   **Feasibility Accelerator**
    *   Generates the feasibility questionnaire for CROs/sponsors, loads site target list, submits feasibility request to sites.
    *   Sites use it to respond to any feasibility request from CROs/Sponsors rapidly
    *   Track all feasibility requests in process. Reduces time to respond.
    *   Leads to more studies matching site capabilities - incl registry

*   **Regulatory Chat**
    *   Search, summarize, and compare multiple regulatory sources and guidance documents.
    *   Drill down to a specific paragraph to cite the source of information.
    *   Aids sites in maintaining docs needed for regulatory audits and educates them

*   **Protocol Chat**
    *   This copilot intelligently summarizes 100s of protocols.
    *   The Protocol Chat Copilot is specifically optimized to provide relevant responses to any kind of queries for any and all protocols.

*   **Proposal Builder**
    *   Helps CROs generate proposals to sponsors and/or sites based on need, in under one hour
    *   Leverages client's data and prior documents, and customizes output based on protocol/variables

*   **Competitive Trial Intelligence**
    *   Analyzes exc/inc criteria of studies in the desired space
    *   Segments successful versus failing studies
    *   Analyzes endpoints of studies
    *   Proposes optimal trial design positioned for success
    *   Accelerates enrollment for studies that are not enrolling timely

©2024 Ryght, Inc. All Rights Reserved. CONFIDENTIAL. Do not distribute or reproduce.

## Slide 16: Site Network Go To Market

**Site Network Go To Market**

**Ryght** (represented by a 3D cube with the Ryght logo) connects to:

*   **Direct**
    *   IDNs
    *   AMCs
*   **SMOs/Networks (Rev Share)**, which connect to various therapeutic areas:
    *   **Oncology:** Site, Site, Site, Site
    *   **Cardio:** Site, Site, Site, Site
    *   **Metabolic:** Site, Site, Site, Site
    *   **Autoimmune:** Site, Site, Site, Site
    *   **Neuro:** Site, Site, Site, Site
    *   **Other:** Site, Site, Site, Site

**Ryght** also connects to:
*   **CRO**
*   **Sponsor**

Both **CRO** and **Sponsor** connect to a **Feasibility App**, which in turn connects to the various therapeutic areas' sites.

© 2024 Ryght, Inc. All Rights Reserved. CONFIDENTIAL. Do not distribute or reproduce.

## Slide 17: Commercial Go To Market

**Commercial Go To Market**

**Top of Funnel (Marketing Channels):**
*   Channel
*   Social
*   SEO/SEM
*   Email
*   PR
*   Advertising

These channels drive traffic to:

**Middle of Funnel (Target Audiences):**
*   CRO
*   Sponsor
*   Healthtech

These audiences then interact with:

**Sales Funnel:**
*   **Land**
    *   **Preview** (leads to Enterprise)
        *   Conversion campaigns to drive Preview users to Enterprise deal funnel
*   **Expand**
    *   **Enterprise** (represented by a branching network of nodes)
        *   Leads converting directly to sales team (without trying preview)

**Sales Motion:**
*   Inside Sales/SDR
*   Direct Sales Team

©2024 Ryght, Inc. All Rights Reserved. CONFIDENTIAL. Do not distribute or reproduce.

## Slide 18: Traction Since January 2024 launch

**Traction Since January 2024 launch**
$460,000 ARR across 6 paid SaaS subscriptions

**Chart: Line graph showing ARR growth over time**
*   Y-axis: ARR in $ (from $0.00 to $40,000.00)
*   X-axis: Date (2/1/2024, 3/1/2024, 4/1/2024, 5/1/2024)

| Date       | ARR ($)     |
|------------|-------------|
| 2/1/2024   | ~14,000     |
| 3/1/2024   | ~9,500      |
| 4/1/2024   | ~18,000     |
| 5/1/2024   | ~32,000     |
| (Implied)  | ~39,000 (at current scale based on line trend) |

*Includes 3 deals confirmed and in legal

©2024 Ryght, Inc. All Rights Reserved. CONFIDENTIAL. Do not distribute or reproduce.

## Slide 19: Competitive Landscape

**Competitive Landscape**

**X-axis: Biopharma expertise** (from General-purpose to Biopharma-specific)
**Y-axis: Enterprise capability** (from Consumer Chatbots to Enterprise)

| Category             | General-purpose & Consumer Chatbots | General-purpose & Enterprise | Biopharma-specific & Consumer Chatbots | Biopharma-specific & Enterprise |
|----------------------|-------------------------------------|------------------------------|----------------------------------------|---------------------------------|
| **Companies**        | Gemini, AI (Google AI logo)         | C3.ai, glean, H2O.ai, PRYON  | Ferma, scite_ (lower capability)        | RIGHT., Autonomize, HUMA.AI, pear |

©2024 Ryght, Inc. All Rights Reserved. CONFIDENTIAL. Do not distribute or reproduce.

## Slide 20: Company Timeline

**Company Timeline**

| Quarter | Event                               | Funding                                                                                                                                                                                                                                                                             |
|---------|-------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1Q23    | Idea Hatched                        |                                                                                                                                                                                                                                                                                     |
| 2Q23    | Company Incorporated, Coding Begins | $3M SAFE Note                                                                                                                                                                                                                                                                       |
| 3Q23    | Signed hcl Commercial Agreement     | Additional $1.25M added to SAFE Note <br> **Investors shown:** virtue., AIX Ventures, PAGE ONE VENTURES, TOP HARVEST CAPITAL, iaso VENTURES                                                                                                                                          |
| 4Q23    | Platform GA Announced               |                                                                                                                                                                                                                                                                                     |
| 1Q24    | 5 new SaaS Licenses Signed          |                                                                                                                                                                                                                                                                                     |
| 2Q24    | Ryght Preview Launch                | SAFE #2                                                                                                                                                                                                                                                                             |

©2024 Ryght, Inc. All Rights Reserved. CONFIDENTIAL. Do not distribute or reproduce.

## Slide 21: Finance

**Finance**
Projections

|                               | **2023 (Actual)** | **2024**       | **2025**       | **2026**       | **2027**       |
|-------------------------------|-------------------|----------------|----------------|----------------|----------------|
| **Customer Metrics (EOY)**    | **$k** | **%**          | **$k** | **%**          | **$k** | **%**          | **$k** | **%**          | **$k** | **%**          |
| Customers                     | -                 | 13             |                | 37             |                | 81             |                | 165            |                |
| ARR ($000s) - SaaS            | -                 | $1,615         |                | $6,384         |                | $16,165        |                | $33,057        |                |
| ARR ($000s) - Network Access  | -                 | $              |                | $500           |                | $9,500         |                | $24,500        |                |
| **Total ARR**                 | **-**             | **$1,615**     |                | **$6,884**     |                | **$25,665**    |                | **$57,557**    |                |
| YoY Growth                    |                   |                |                | 295%           |                | 153%           |                | 104%           |                |
|                               |                   |                |                |                |                |                |                |                |                |
| **Revenue - SaaS**            | -                 | 348            | 100%           | 3,280          | 96%            | 10,622         | 72%            | 23,672         | 56%            |
| Revenue - Network Access      | -                 | 0              | 0%             | 125            | 4%             | 4,188          | 28%            | 18,250         | 44%            |
| **Total Revenue**             | **-**             | **348**        | **100%**       | **3,405**      | **100%**       | **14,809**     | **100%**       | **41,922**     | **100%**       |
| Cost of revenue*              | -                 | 214            | 61%            | 1,074          | 33%            | 2,517          | 24%            | 5,010          | 21%            |
| **Gross profit**              | **-**             | **134**        | **39%**        | **2,331**      | **68%**        | **12,292**     | **83%**        | **36,912**     | **88%**        |
|                               |                   |                |                |                |                |                |                |                |                |
| **Operating Expenses**        |                   |                |                |                |                |                |                |                |                |
| Product Development           | 738               | 1,765          | 508%           | 2,746          | 81%            | 4,433          | 30%            | 6,272          | 15%            |
| Sales                         | 508               | 456            | 131%           | 1,035          | 30%            | 2,687          | 18%            | 5,230          | 12%            |
| Marketing                     | -                 | 493            | 142%           | 700            | 21%            | 1,275          | 9%             | 2,064          | 5%             |
| General & Administrative      | 497               | 976            | 281%           | 1,594          | 47%            | 2,017          | 14%            | 2,643          | 6%             |
| **Total Operating Expense**   | **1,743**         | **3,690**      | **1062%**      | **6,075**      | **178%**       | **10,413**     | **70%**        | **16,209**     | **39%**        |
|                               |                   |                |                |                |                |                |                |                |                |
| **EBITDA**                    | **(1,743)**       | **(3,556)**    | **-1023%**     | **(3,743)**    | **-110%**      | **1,879**      | **13%**        | **20,703**     | **49%**        |
|                               |                   |                |                |                |                |                |                |                |                |
| **Headcount**                 | 9                 | 25             |                | 49             |                | 62             |                | 79             |                |
| Revenue Per Employee ($000s)| $                 | $14            |                | $67            |                | $171           |                | $300           |                |
| EBITDA Per Employee ($000s)   | $(194)$           | $(142)$        |                | $(76)$         |                | $30            |                | $262           |                |
| Ending Cash (000s)            | $3,100            | $1,063         |                | $6,455         |                | $5,678         |                | $22,908        |                |
|                               |                   |                |                |                |                |                |                |                |                |
| **Funding Plan**              |                   | **1,580**      | **Q2**         | **10,000**     | **Q1**         |                |                |                |                |

©2024 Ryght, Inc. All Rights Reserved. CONFIDENTIAL. Do not distribute or reproduce.

## Slide 22: Current Customers

**Current Customers**

* all customers are able to leverage copilot Builder

| Company    | Company Type       | Co-pilots*                                   | Number of Users | EOY ARR     |
|:-----------|:-------------------|:---------------------------------------------|:----------------|:------------|
| McKesson   | RWE, Site, CRO     | EMR Extraction & Trial Docs                  | 14              | $150,000    |
| Hcl        | Lab Tech           | Disease Research & Misc. Test                | 10              | $90,000     |
| Nmible     | Trial Tech         | Trial Participant Reimbursement              | 4               | $145,000    |
| Surge      | Biotech            | Disease Research, Trial Docs                 | 2               | $25,000     |
| Bek Health | Site Tech          | Feasibility                                  | 2               | $25,000     |
| Avance     | CRO                | Feasibility                                  | 0               | $25,000     |
| Sargon     | Trial Site         | Chat with Protocol, Chat with IB, Feasibility (future) | 4               | NA          |
| SOCRU      | Trial Site         | Chat with Protocol, Chat with IB, Feasibility (future) | 8               | NA          |
| **Total**  |                    |                                              | **42**          | **$460,000**|

©2024 Ryght, Inc. All Rights Reserved. CONFIDENTIAL. Do not distribute or reproduce.

## Slide 23: Internal Simon Crib Notes

**Internal Simon Crib Notes**

* all customers are able to leverage copilot Builder

| Company    | Company Type       | Co-pilots*                                   | Number of Users | Reference     | EOY ARR     |
|:-----------|:-------------------|:---------------------------------------------|:----------------|:--------------|:------------|
| McKesson   | RWE, Site, CRO     | EMR Extraction & Trial Docs                  | 14              |               | $150,000    |
| Hcl        | Lab Tech           | Disease Research & Misc. Test                | 10              | Bill, Charlie | $90,000     |
| Nmible     | Trial Tech         | Trial Participant Reimbursement              | 4               | Jon           | $145,000    |
| Surge      | Biotech            | Disease Research, Trial Docs                 | 2               | Shane         | $25,000     |
| Bek Health | Site Tech          | Feasibility                                  | 2               |               | $25,000     |
| Avance     | CRO                | Feasibility                                  | 0               |               | $25,000     |
| Sargon     | Trial Site         | Chat with Protocol, Chat with IB, Feasibility (future) | 4               | Carrie        | NA          |
| SOCRU      | Trial Site         | Chat with Protocol, Chat with IB, Feasibility (future) | 8               |               | NA          |
| **Total**  |                    |                                              | **42**          |               | **$460,000**|

©2024 Ryght, Inc. All Rights Reserved. CONFIDENTIAL. Do not distribute or reproduce.

## Slide 24: Fundraising

**Fundraising**
SAFE Note $3M (Q2 2024); $10M+ Series A Q4 '24

*   **Product:**
    *   Grow enterprise functionality
    *   Release self-service no code copilot builder and build 30+ copilots
    *   Develop more enterprise connectors
    *   Complete and distribute “feasibility accelerator"
*   **Marketing & Commercialization:**
    *   Position as the defacto GenAI platform provider and AI-enabled site network
    *   Push co-pilot content (videos, webinars etc) to drive demand to sponsors and sites
    *   Build direct sales force and BDMs across key partners
    *   Prove repeatable sales model for sites and customers

©2024 Ryght, Inc. All Rights Reserved. CONFIDENTIAL. Do not distribute or reproduce.

## Slide 25: Thank you!

**Thank you!**

Simon Arkell
CEO, Co-founder
simon@ryght.ai

Alex Dickinson
Exec Chair, Co-founder
alex@ryght.ai

© 2024 Ryght, Inc. All Rights Reserved. CONFIDENTIAL. Do not distribute or reproduce.